Skip to main content

Table 1 Patients’ characteristics

From: Clinical outcome of surgical management for symptomatic metastatic spinal cord compression from prostate cancer

 

Patients with mHNPC (n = 8)

Patients with mCRPC (n = 11)

Variables at initial diagnosis of prostate cancer

Median prostate-specific antigen (range), ng/mL

910 (98–8900)

232 (6–4271)

Biopsy Gleason scores, n (%)

  ≤ 7

0 (0.0%)

2 (18.2%)

 8–10

5 (62.5%)

9 (81.8%)

 Unknown

3 (37.5%)

0 (0.0%)

Extent of disease on bone scan

 0

0 (0.0%)

4 (36.4%)

 1

2 (25.0%)

2 (18.2%)

 2

1 (12.5%)

1 (9.1%)

 3

1 (12.5%)

1 (9.1%)

 4

0 (0.0%)

0 (0.0%)

 Unknown

4 (50.0%)

3 (27.3%)

Variables at decompression surgery

Median age (range), years

72 (62–78)

65 (46–71)

Median prostate-specific antigen (range), ng/mL

910 (98–8900)

67 (0.1–307)

Lesion of decompression surgery, n (%)

 Cervical spine

0 (0.0%)

1 (9.1%)

 Cervical-thoracic spine

0 (0.0%)

2 (18.2%)

 Thoracic spine

6 (75.0%)

6 (54.5%)

 Thoracic-lumbar spine

0 (0.0%)

1 (9.1%)

 Lumbar spine

2 (25.0%)

1 (9.1%)

Median time to decompression surgery from symptoms occurrence (range), days

4 (0–8)

2 (0–14)

The use of bone-targeted agentsa, n (%)

0 (0.0%)

4 (36.3%)

  1. mHNPC Metastatic hormone-naïve prostate cancer, mCRPC Metastatic castration-resistant prostate cancer
  2. aZoledronic acid or denosumab